alector.com
Get leads like Alector — and thousands more
Build targeted lists by tech stack, traffic, and more
Alector: The $197M Bet on Neuroimmunology
How a biotech with low traffic is tackling dementia's biggest mysteries
In a world where biotech websites scream for attention, alector.com whispers with quiet confidence. With just 6,115 monthly visits but $197M in revenue, this isn't a company chasing clicks—it's a company chasing cures for dementia.
"Alector proves that in biotech, traffic is vanity. Revenue is sanity. Cures are the only metric that matters."
The Neuroimmunology Play
Alector isn't chasing trendy mRNA or gene therapy. They're deep in the weeds of neuroimmunology—specifically targeting TREM2 and MS4A proteins to treat frontotemporal dementia (FTD) and Lewy body dementia. Their lead candidate, AL001, shows the kind of focused conviction that venture-backed biotechs often lack. While others spray shots across the board, Alector is methodically dismantling dementia's immune system connection.
The Traffic Paradox
Here's what's fascinating: 44% of their traffic is direct—people typing 'alector.com' into their browser. That's not a startup building brand awareness; that's a company with institutional recognition. For a biotech with only 6,115 monthly visits, this signals a highly specialized audience: researchers, clinicians, and investors who already know who they are. The 37% organic search traffic is dominated by technical queries like 'biotech lewy body dementia'—not broad awareness terms.
The keyword strategy reveals their precision targeting. 'Alector' (780 monthly volume) captures brand search, but 'AL001' (220 volume) and 'invoke-2 trial trem2' (70 volume) show they're speaking directly to the scientific community. This isn't mass-market marketing—it's surgical stakeholder engagement.
- TREM2-targeting approach for FTD: A unique angle on dementia's immune response
- MS4A protein platform: Building a pipeline beyond their lead candidate
- Invoke-2 trial: Active clinical validation of their hypothesis
- Low traffic, high intent: 44% direct traffic suggests strong institutional awareness
The Quiet Giant of Neuroimmunology
With $194.5M in funding and 325 employees, Alector isn't playing for a quick exit—they're building a legacy in dementia treatment. Their website reflects this: functional, technical, and utterly unconcerned with vanity metrics. In a sector where hype often outpaces science, Alector's restraint is its most compelling feature.
What tech stack does Alector use?
How much traffic does Alector get?
Traffic & Engagement
Traffic Sources
Where is Alector's audience located?
What keywords does Alector rank for?
5 keywordsWhat is Alector's revenue?
Who competes with Alector?
Who works at Alector?
Loading leads...
What do customers think of Alector?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Alector
What is Alector's Revenue?
How fast is Alector growing?
What technologies does Alector use?
Who are Alector's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
Export alector.com Data
Download the complete tech stack, analytics, leads, and company data for alector.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About alector.com
Company Overview
Technology Stack
alector.com uses 15 technologies across their website including Adobe Fonts, HSTS, PHP, and more.
Fonts
Adobe Fonts
Security
HSTS
Programming Languages
PHP
CMS
WordPress
CDN
unpkg
Privacy & Consent
OneTrust
Traffic & Audience
alector.com receives approximately 6.1K monthly visitors and ranks #3,370,379 globally. The website has a bounce rate of 47% with visitors viewing an average of 1.5 pages per visit. Users spend an average of 0:29 on the site.
The majority of alector.com's traffic comes from undefined, undefined, .
Frequently Asked Questions
What is alector.com?
What technologies does alector.com use?
How popular is alector.com?
Related Searches
This page provides publicly available information about alector.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit alector.com directly at https://alector.com.